Drug-drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients. (PubMed, J Antimicrob Chemother) - Mar 5, 2025 - "Letermovir significantly decreased CsA metabolism in HSCT patients through CYP3A4 inhibition, with clinical implications for dosing precision. Close therapeutic drug monitoring (generally twice weekly) is therefore recommended during letermovir initiation and discontinuation to mitigate risks of subtherapeutic levels or toxicity. This study highlights the significance of assessing DDIs in HSCT, where inflammation modulates metabolic interactions resulting in a complex interplay such as a disease-drug-drug interaction (D-DDI)."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Inflammation • Transplantation • CRP
|
|
David Malnoë; Mathilde Bories; Pascal Le Corre; Tony Marchand
|